Navigation Links
Lung Infections-Pipeline Insights, 2014
Date:9/3/2014

LONDON, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Infections-Pipeline Insights, 2014

http://www.reportlinker.com/p02278635/-Lung-Infections-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Lung Infections-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lung Infections. This report provides information on the therapeutic development based on the Lung Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Lung Infections
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lung Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lung Infections and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lung Infections
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lung Infections pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Lung Infections Overview
- Lung Infections Pipeline Therapeutics
- Lung Infections Therapeutics under Development by Companies
- Lung Infections Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lung Infections Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Lung Infections Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lung Infections Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lung Infections – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Infections – Discontinued Products
- Lung Infections – Dormant Products
- Companies Involved in Therapeutics Development for Lung Infections
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lung Infections, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lung Infections Assessment by Monotherapy Products
- Lung Infections Assessment by Combination Products
- Lung Infections Assessment by Route of Administration
- Lung Infections Assessment by Stage and Route of Administration
- Lung Infections Assessment by Molecule Type
- Lung Infections Assessment by Stage and Molecule Type
- Lung Infections Therapeutics – Discontinued Products
- Lung Infections Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lung Infections, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lung Infections Assessment by Monotherapy Products
- Lung Infections Assessment by Combination Products
- Lung Infections Assessment by Route of Administration
- Lung Infections Assessment by Stage and Route of Administration
- Lung Infections Assessment by Molecule Type
- Lung Infections Assessment by Stage and Molecule Type

To order this report: Lung Infections-Pipeline Insights, 2014
http://www.reportlinker.com/p02278635/-Lung-Infections-Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Injury-Pipeline Insights, 2014
2. Lupus Nephritis-Pipeline Insights, 2014
3. Lyme Disease-Pipeline Insights, 2014
4. Lymphedema-Pipeline Insights, 2014
5. Leg Ulcers-Pipeline Insights, 2014
6. Lipodystrophy-Pipeline Insights, 2014
7. Liposarcoma -Pipeline Insights, 2014
8. Liver Cirrhosis-Pipeline Insights, 2014
9. Liver Diseases-Pipeline Insights, 2014
10. Liver Fibrosis-Pipeline Insights, 2014
11. Liver Transplantation-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve ... Health and the U.S. Soccer Foundation announced today that they have awarded nine ... for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 ... honors those who have made notable contributions to the staffing industry over the ...
(Date:2/17/2017)... CREEK, CO (PRWEB) , ... February 17, 2017 , ... ... second annual International Healing NET Foundation Summit from February 21 - 23 in Beaver ... NET Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over ...
(Date:2/16/2017)... York (PRWEB) , ... February 17, 2017 , ... ... determination. After what took over 10 years of research, development and clinical trials, ... Technology™. NTX Technology™ is a patented compound of FDA approved ingredients that when ...
(Date:2/16/2017)... ... February 17, 2017 , ... The Price Agency, a Jefferson ... entrepreneurs in the Birmingham area, is announcing an ongoing charity event to help ... medically challenged son, Anius. , Anius is medically complex with diagnoses consisting and ...
Breaking Medicine News(10 mins):